Brief: Abcellera & Rallybio To Develop Novel Antibody-Based Therapeutics For Rare Diseases
01/12/2022 12:27
Dec 1 (Reuters) - Abcellera Biologics Inc ABCL.O :
* ABCELLERA AND RALLYBIO ANNOUNCE STRATEGIC ALLIANCE TO
DISCOVER,
DEVELOP, AND COMMERCIALIZE NOVEL ANTIBODY-BASED THERAPEUTICS FOR
RARE DISEASES
Source text for Eikon: ID:nBw70rx3Ga
Further company coverage: ABCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rallybio
See all newsNASDAQ RESUMED AT 08:48 AM
Brief: Rallybio Corporation And Avenzo Therapeutics Announce Merger Agreement To Advance Next-Generation Oncology Therapies And $215 Million Concurrent Private Placement
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE-Mirum Pharma
U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx